Sign up
Pharma Capital

InMed Pharmaceuticals disrupting cannabinoid space with biosynthesis technology

InMed Pharmaceuticals Inc (TSX:IN; OTCQX:IMLFF) Chief Business Officer Josh Blacher speaks with Proactive Investor's Christine Corrado about how the biopharma company is changing the game in the cannabinoid space.

Blacher says the Vancouver based company, which specializes in developing therapeutics to treat a variety of diseases, is disrupting the space with its cannabinoid biosynthesis technology, which aims to manufacture any of the more than 90 variations of cannabinoids, resulting in products that are bio-identical to the naturally occurring cannabinoids in the cannabis plant.

 

View full IN profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.